Term | Description |
abatacept | Abatacept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required (Section 100 only). Providing the patient meets specific restriction criteria, abatacept is subsidised for the treatment of rheumatoid arthritis. |
adalimumab | Adalimumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required (Section 100 only). Providing the patient meets specific restriction criteria, adalimumab is subsidised for the treatment of: - ankylosing spondylitis
- Crohn's disease:
- enthesitis/spondylitis juvenile idiopathic arthritis
- fistulising Crohn's disease
- hidradenitis suppurativa
- juvenile idiopathic arthritis
- non-infectious uveitis
- psoriatic arthritis
- rheumatoid arthritis
- severe chronic plaque psoriasis: adult
- ulcerative colitis:
|
aflibercept | Aflibercept is a Section 85 listed pharmaceutical benefit. Providing the patient meets specific restriction criteria, aflibercept is subsidised for the treatment of: - diabetic macular oedema
- retinal vein occlusion with macular oedema
- subfoveal choroidal neovascularisation due to:
- age related macular degeneration
- pathologic myopia
- other causes
|
ambrisentan | Ambrisentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, ambrisentan is subsidised for the treatment of pulmonary arterial hypertension. |
anifrolumab | Anifrolumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, anifrolumab is subsidised for the treatment of systemic lupus erythematosus. |
armodafinil | Armodafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, armodafinil is subsidised for the treatment of narcolepsy. |
asciminib | Asciminib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, asciminib is subsidised for the treatment of chronic myeloid leukaemia. |
avatrombopag | Avatrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, avatrombopag is subsidised for the treatment of idiopathic thrombocytopenic purpura. |
azacitidine | Azacitidine is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, azacitidine is subsidised for the treatment of: - myelodysplastic syndrome
- chronic myelomonocytic leukaemia
- acute myeloid leukaemia
|
baricitinib | Baricitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, baricitinib is subsidised for the treatment of rheumatoid arthritis. |
benralizumab | Benralizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, benralizumab is subsidised for the treatment of: |
bimekizumab | Bimekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, bimekizumab is subsidised for the treatment of: - non-radiographic axial spondyloarthritis
- ankylosing spondylitis
- hidradenitis suppurativa
- psoriatic arthritis
- severe chronic plaque psoriasis: adult
|
blinatumomab | Blinatumomab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, blinatumomab is subsidised for the treatment of acute lymphoblastic leukaemia. |
bosentan monohydrate | Bosentan monohydrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, bosentan monohydrate is subsidised for the treatment of pulmonary arterial hypertension. |
brentuximab vedotin | Brentuximab vedotin is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, brentuximab is subsidised for the treatment of: - CD30 positive systemic anaplastic large cell lymphoma
- relapsed or refractory Hodgkin lymphoma
- cutaneous T-cell lymphoma
- peripheral T-cell lymphoma
- stage III or IV CD30 positive Hodgkin lymphoma
|
brolucizumab | Brolucizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, brolucizumab is subsidised for the treatment of age related macular degeneration (AMD). |
burosumab | Burosumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, burosumab is subsidised for the treatment of X-linked hypophosphataemia (XLH). |
certolizumab pegol | Certolizumab pegol is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, certolizumab is subsidised for the treatment of: - rheumatoid arthritis
- ankylosing spondylitis
- psoriatic arthritis
- non-radiographic axial spondyloarthritis
|
crizotinib | Crizotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, crizotinib is subsidised for the treatment of Stage IIIB or Stage IV non-small-cell lung cancer. |
daratumumab | Daratumumab is a Section 85 and 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, daratumumab is subsidised for the treatment of untreated multiple myeloma. |
dasatinib | Dasatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, dasatinib is subsidised for the treatment of: - acute lymphoblastic leukaemia
- chronic myeloid leukaemia
|
daunorubicin+cytarabine | Daunorubicin+cytarabine is listed under Section 100 – Efficient funding of chemotherapy arrangements and administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, daunorubicin+cytarabine is subsidised for the treatment of acute myeloid leukaemia. |
decitabine+cedazuridine | Decitabine+cedazuridine is a Section 85 listed pharmaceutical benefit. Providing the patient meets specific restriction criteria, decitabine+cedazuridine is subsidised for the treatment of: - acute myeloid leukaemia
- chronic myelomonocytic leukaemia
- myelodysplastic syndrome
|
dexamethasone implant | Dexamethasone is a Section 85 listed pharmaceutical benefit. Providing the patient meets the specific restriction criteria, dexamethasone implant is subsidised for the treatment of: - diabetic macular oedema
- retinal vein occlusion macular oedema
|
difelikefalin | Difelikefalin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, difelikefalin is subsidised for the treatment of chronic kidney disease-associated pruritus. |
dupilumab | Dupilumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, dupilumab is subsidised for the treatment of severe asthma. |
eculizumab | Eculizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, eculizumab is subsidised for the treatment of: - atypical haemolytic uraemic syndrome
- paroxysmal nocturnal haemoglobinuria
|
eflornithine | Eflornithine is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, eflornithine is subsidised for the treatment of high-risk neuroblastoma. |
elexacaftor+tezacaftor+ivacaftor | Elexacaftor+tezacaftor+ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, elexacaftor+tezacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis. |
elotuzumab | Elotuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, elotuzumab is subsidised for the treatment of multiple myeloma. |
eltrombopag | Eltrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, eltrombopag is subsidised for the treatment of: - idiopathic thrombocytopenic purpura
- severe aplastic anaemia
|
entrectinib | Entrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, entrectinib is subsidised for the treatment of Stage IIIB or Stage IV non-small-cell lung cancer. |
epoprostenol sodium | Epoprostenol sodium is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, epoprostenol sodium is subsidised for the treatment of pulmonary arterial hypertension. |
etanercept | Etanercept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required (Section 100 only). Providing the patient meets specific restriction criteria, etanercept is subsidised for the treatment of: - ankylosing spondylitis
- juvenile idiopathic arthritis
- psoriatic arthritis
- rheumatoid arthritis
- severe chronic plaque psoriasis:
|
etrasimod | Etrasimod is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, etrasimod is subsidised for the treatment of ulcerative colitis. |
faricimab | Faricimab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, faricimab is subsidised for the treatment of: - diabetic macular oedema
- branch retinal vein occlusion with macular oedema
- central retinal vein occlusion with macular oedema
- subfoveal choroidal neovascularisation due to age related macular degeneration
|
garadacimab | Garadacimab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, garadacimab is subsidised for the chronic treatment of hereditary angioedema Types 1 or 2. |
givosiran | Givosiran is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team. Providing the patient meets specific restriction criteria, givosiran is subsidised for the chronic treatment of Acute Hepatic Porphyria. |
golimumab | Golimumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team. Providing the patient meets specific restriction criteria, golimumab is subsidised for the treatment of: - ankylosing spondylitis
- ulcerative colitis: adult
- psoriatic arthritis
- rheumatoid arthritis
- non-radiographic axial spondyloarthritis
|
guselkumab | guselkumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team. Providing the patient meets specific restriction criteria, guselkumab is subsidised for the treatment of: - Psoriatic arthritis
- Severe chronic plaque psoriasis: adult
|
iloprost trometamol | Iloprost trometamol is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, iloprost trometamol is subsidised for the treatment of pulmonary arterial hypertension. |
imatinib | Imatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, imatinib is an agent subsidised for the treatment of: - chronic myeloid leukaemia
- gastrointestinal stromal tumour
- acute lymphoblastic leukaemia
|
infliximab | Infliximab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required (Section 100 only). Providing the patient meets specific restriction criteria, infliximab is subsidised for the treatment of: - ankylosing spondylitis
- Crohn's disease:
- adults
- paediatric (Section 100 only)
- fistulising Crohn's disease
- psoriatic arthritis
- rheumatoid arthritis
- severe chronic plaque psoriasis: adults
- ulcerative colitis:
- adult
- paediatric (Section 100 only)
|
inotuzumab ozogamicin | Inotuzumab ozogamicin is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, inotuzumab ozogamicin is subsidised for the treatment of acute lymphoblastic leukaemia. |
iptacopan | Iptacopan is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, iptacopan is subsidised for the treatment of paroxysmal nocturnal haemoglobinuria. |
ivacaftor | Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, ivacaftor is subsidised for the treatment of cystic fibrosis. |
ixekizumab | Ixekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, ixekizumab is subsidised for the treatment of: - ankylosing spondylitis
- psoriatic arthritis
- severe chronic plaque psoriasis: adult
|
lanadelumab | Lanadelumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, lanadelumab is subsidised for the treatment of hereditary angioedema type 1 or 2. |
lapatinib | Lapatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, lapatinib is subsidised for the treatment of metastatic breast cancer. |
larotrectinib | Larotrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, larotrectinib is subsidised for the treatment of solid tumours that are confirmed to be neurotrophic tropomyosin receptor kinase (NTRK) gene fusion positive. |
lenalidomide | Lenalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, lenalidomide is subsidised for the treatment of: - multiple myeloma
- myelodysplastic syndrome
|
lumacaftor+ivacaftor | Lumacaftor+ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, lumacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis. |
lumasiran | Lumasiran is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, lumasiran is subsidised for the treatment of primary hyperoxaluria type 1. |
macitentan | Macitentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, macitentan is subsidised for the treatment of pulmonary arterial hypertension. |
macitentan+tadalafil | Macitentan+tadalafil is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, macitentan+tadalafil is subsidised for the continuing treatment of pulmonary arterial hypertension. |
mavacamten | Mavacamten is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, mavacamten is subsidised for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. |
mecasermin | Mecasermin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, mecasermin is subsidised for the treatment of severe growth failure with primary insulin-like growth factor-1 deficiency. |
mepolizumab | Mepolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, mepolizumab is subsidised for the treatment of: - severe asthma:
- chronic rhinosinusitis with nasal polyps (CRSwNP)
|
midostaurin | Midostaurin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, midostaurin is subsidised for the treatment of acute myeloid leukaemia. |
migalastat | Migalastat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, migalastat is subsidised for the treatment of Fabry disease. |
modafinil | Modafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, modafinil is subsidised for the treatment of narcolepsy. |
mogamulizumab | Mogamulizumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets the specific restriction criteria, mogamulizumab is subsidised for the treatment of cutaneous T-cell lymphoma. |
nilotinib | Nilotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, nilotinib is subsidised for the treatment of chronic myeloid leukaemia. |
nintedanib | Nintedanib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, nintedanib is subsidised for the treatment of: - idiopathic pulmonary fibrosis
- progressive fibrosing interstitial lung disease
|
nusinersen | Nusinersen is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, nusinersen is subsidised for the treatment of spinal muscular atrophy. |
odevixibat | Odevixibat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, odevixibat is subsidised for the treatment of progressive familial intrahepatic cholestasis disease. |
omalizumab | Omalizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, omalizumab is subsidised for the treatment of: - severe asthma
- chronic spontaneous urticaria
|
onasemnogene abeparvovec | Onasemnogene abeparvovec is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public hospital authority required. Providing the patient meets specific restriction criteria, onasemnogene abeparvovec is subsidised for the treatment of spinal muscular atrophy. |
ozanimod | Ozanimod is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, ozanimod is subsidised for the treatment of ulcerative colitis (adult). |
palovarotene | Palovarotene is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, palovarotene is subsidised for the treatment of fibrodysplasia ossificans progressiva. |
pasireotide | Pasireotide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority is required. Providing the patient meets specific restriction criteria, pasireotide is subsidised for the treatment of acromegaly. |
patisiran | Patisiran is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority is required. Providing the patient meets specific restriction criteria, patisiran is subsidised for the treatment of hereditary transthyretin amyloidosis. |
pegcetacoplan | Pegcetacoplan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, pegcetacoplan is subsidised for the treatment of paroxysmal nocturnal haemoglobinuria. |
pegvisomant | Pegvisomant is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority is required. Providing the patient meets specific restriction criteria, pegvisomant is subsidised for the treatment of acromegaly. |
pertuzumab | Pertuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, pertuzumab is subsidised for the treatment of metastatic breast cancer. |
pirfenidone | Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, pirfenidone is subsidised for the treatment of idiopathic pulmonary fibrosis. |
polylactic acid | Polylactic acid is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, polylactic acid is subsidised for the treatment of severe facial lipoatrophy. |
pomalidomide | Pomalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, pomalidomide is subsidised for the treatment of multiple myeloma. |
ponatinib | Ponatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, ponatinib is an agent subsidised for the treatment of: - chronic myeloid leukaemia
- acute lymphoblastic leukaemia
|
ranibizumab | Ranibizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, ranibizumab is subsidised for the treatment of: - diabetic macular oedema
- retinal vein occlusion with macular oedema
- subfoveal choroidal neovascularisation due to:
- age related macular degeneration
- pathologic myopia
- other causes
|
ravulizumab | Ravulizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, ravulizumab is subsidised for the treatment of: - paroxysmal nocturnal haemoglobinuria
- atypical haemolytic uraemic syndrome
- neuromyelitis optica spectrum disorder
- generalised myasthenia gravis
|
repotrectinib | Repotrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, repotrectinib is subsidised for the treatment of Stage IIIB or Stage IV non-small-cell lung cancer. |
riociguat | Riociguat is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, riociguat is subsidised for the treatment of: - pulmonary arterial hypertension
- chronic thromboembolic pulmonary hypertension
|
ripretinib | Ripretinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, ripretinib is subsidised for the treatment of gastrointestinal stromal tumour. |
risankizumab | Risankizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, risankizumab is subsidised for the treatment of: - severe psoriatic arthritis
- severe chronic plaque psoriasis: adult
|
risdiplam | Risdiplam is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, risdiplam is subsidised for the treatment of spinal muscular atrophy. |
romiplostim | Romiplostim is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, romiplostim is subsidised for the treatment of idiopathic thrombocytopenic purpura. |
ruxolitinib | Ruxolitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, ruxolitinib is subsidised for the treatment of polycythemia vera. |
secukinumab | Secukinumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, secukinumab is subsidised for the treatment of: - ankylosing spondylitis
- hidradenitis suppurativa
- severe chronic plaque psoriasis: adult
- psoriatic arthritis
- non-radiographic axial spondyloarthritis
|
selexipag | Selexipag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, selexipag is subsidised for the treatment of pulmonary arterial hypertension. |
selumetinib | Selumetinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, selumetinib is subsidised for the treatment of neurofibromatosis type 1. |
sildenafil citrate | Sildenafil citrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, sildenafil citrate is subsidised for the treatment of pulmonary arterial hypertension. |
somatrogon | Somatrogon is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, somatrogon is subsidised for the treatment of growth hormone deficiency (paediatric). |
somatropin | Somatropin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, somatropin is subsidised for the treatment of growth hormone deficiency. |
sonidegib | Sonidegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, sonidegib is subsidised for the treatment of basal cell carcinoma. |
sunitinib malate | Sunitinib malate is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, sunitinib malate is subsidised for the treatment of malignant gastrointestinal stromal tumour. |
tadalafil | Tadalafil is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, tadalafil is used to treat patients with pulmonary arterial hypertension. |
tafamidis | Tafamidis is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, tafamidis is subsidised for the treatment of transthyretin amyloid cardiomyopathy. |
teduglutide | Teduglutide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, teduglutide is subsidised for the treatment of short bowel syndrome with intestinal failure. |
tezacaftor+ivacaftor | Tezacaftor+ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, tezacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis. |
tildrakizumab | Tildrakizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, tildrakizumab is subsidised for the treatment of severe chronic plaque psoriasis: adult |
tocilizumab | Tocilizumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through PBS Complex Drugs team. Public and private hospital authority required (section 100 listing only). Providing the patient meets specific restriction criteria, tocilizumab is subsidised for the treatment of: - rheumatoid arthritis
- systemic juvenile idiopathic arthritis
- juvenile idiopathic arthritis
- giant cell arteritis
|
tofacitinib | Tofacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, tofacitinib is subsidised for the treatment of: - ankylosing spondylitis
- juvenile idiopathic arthritis
- psoriatic arthritis
- rheumatoid arthritis
- ulcerative colitis: adult
|
trastuzumab | Trastuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, trastuzumab is subsidised for the treatment of: - metastatic breast cancer
- early human epidermal growth factor receptor 2 positive breast cancer
- gastric cancer
|
trastuzumab emtansine | Trastuzumab emtansine is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, trastuzumab emtansine is subsidised for the treatment of: - metastatic breast cancer
- early human epidermal growth factor receptor 2 positive breast cancer
|
upadacitinib | Upadacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, upadacitinib is subsidised for the treatment of: - ankylosing spondylitis
- Crohn's disease: adult
- non-radiographic axial spondyloarthritis
- psoriatic arthritis
- rheumatoid arthritis
- ulcerative colitis: adult
|
ustekinumab | Ustekinumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required (Section 100 only). Providing the patient meets specific restriction criteria, ustekinumab is subsidised for the treatment of: - severe chronic plaque psoriasis
- psoriatic arthritis
- Crohn's disease: adult
- fistulising Crohn's disease
- ulcerative colitis: adult
|
vanzacaftor+tezacaftor+deutivacaftor | Vanzacaftor+tezacaftor+deutivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets the specific restriction criteria, vanzacaftor+tezacaftor+deutivacaftor is subsidised for the treatment of cystic fibrosis. |
vedolizumab | Vedolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority required. Providing the patient meets specific restriction criteria, vedolizumab is subsidised for the treatment of: - Crohn's disease: adult
- chronic pouchitis
- ulcerative colitis: adult
|
vismodegib | Vismodegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, vismodegib is subsidised for the treatment of basal cell carcinoma. |
vorinostat | Vorinostat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Providing the patient meets specific restriction criteria, vorinostat is subsidised for the treatment of cutaneous T-cell lymphoma. |
vutrisiran | Vutrisiran is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority is required. Providing the patient meets specific restriction criteria, vutrisiran is subsidised for the treatment of hereditary transthyretin amyloidosis. |
zilucoplan | Zilucoplan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team. Public and private hospital authority is required. Providing the patient meets specific restriction criteria, zilucoplan is subsidised for the treatment of generalised myasthenia gravis. |
Expand all